BaoLing-FuJin Biotech Announces 2025 Q4 Earnings: EPS of NT$2.22
BaoLing-FuJin Biotech Co., Ltd. (Stock Code: 1760) has released its financial results for the fourth quarter of 2025. The company reported basic earnings per share (EPS) of NT$2.22 for the quarter. Quarterly operating revenue reached NT$2.063 billion, with a net profit after tax of NT$190 million. BaoLing-FuJin continues its development in the biotechnology and medical sector.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:20 (16h 20m after Collected)
Company Code: 1760
Company Name: BaoLing-FuJin Biotech Co., Ltd.
Industry: Biotechnology and Medical
Year/Quarter: 2025 Q4
Basic Earnings Per Share: NT$2.22
Operating Revenue: NT$2.063 billion
Net Profit After Tax: NT$190 million
Company Name: BaoLing-FuJin Biotech Co., Ltd.
Industry: Biotechnology and Medical
Year/Quarter: 2025 Q4
Basic Earnings Per Share: NT$2.22
Operating Revenue: NT$2.063 billion
Net Profit After Tax: NT$190 million
FAQ
What were BaoLing-FuJin Biotech's earnings per share in Q4 2025?
BaoLing-FuJin Biotech reported basic earnings per share of NT$2.22 for the fourth quarter of 2025.
What was BaoLing-FuJin Biotech's operating revenue in Q4 2025?
The company's operating revenue for the fourth quarter of 2025 was NT$2.063 billion.
What was BaoLing-FuJin Biotech's net profit after tax in Q4 2025?
BaoLing-FuJin Biotech's net profit after tax for the fourth quarter of 2025 was NT$190 million.